Article Per Year (5 Year)
p-Index From 2020 - 2025
0.751
P-Index
This Author published in this journals
All Journal Ophthalmologica Indonesiana
Paramitha, Dewa Ayu Anggi
Unknown Affiliation
Health Professions Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
EFFECT OF CAFFEINE CONSUMPTION ON INTRAOCULAR PRESSURE AND RISK OF GLAUCOMA: A SYSTEMATIC REVIEW Paramitha, Dewa Ayu Anggi; Azhari, Fierda Ovita; Anthea Casey; Eldinia, Lourisa Ruth
Majalah Oftalmologi Indonesia Vol 50 No 2 (2024): Ophthalmologica Indonesiana
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/journal.v50i2.100985

Abstract

INTRODUCTION AND OBJECTIVES Glaucoma is one of the leading causes of blindness worldwide with intraocular pressure (IOP) as its main risk factor. Several studies have investigated the association between IOP and caffeine consumption with mixed results. This study aims to review whether caffeine consumption increases IOP thus, increases the risk of glaucoma. METHODS A comprehensive literature search was performed in 4 databases, including Pubmed, Proquest, ScienceDirect, and Cochrane. Last search was conducted on March 20, 2023. We include human studies investigating caffeine impact on IOP and/or glaucoma risk published in English with full text available from 2013 to 2023. The risk of bias was assessed with RoB 2.0 for crossover studies, NIH for cross-sectional and case-control studies. We present our results according to PRISMA guidelines. RESULT A total of 130.012 participants from 7 different studies were included in this review. Three crossover, 3 cross-sectional, and 1 case-control study were evaluated. This study involved a multi-racial population although Caucasian predominated. Five out of 7 studies exhibited a significant association (all p values <0.05) between caffeine consumption and increased risk of developing glaucoma. CONCLUSION Caffeine consumption generally shows a significant impact on developing risk of glaucoma and has been shown to increase IOP in acute settings, reported up to 90 minutes after consumption/ingestion. Limitations of this study include a small number of crossover participants and a high variability of participants (young healthy individuals and glaucoma patients). Further research is advised to investigate the association between caffeine consumption in a longer follow-up time and a more specific population.
Reducing Treatment Burden for Age-Related Macular Degeneration Patients: A Systematic Review of Ranibizumab Port Delivery System: Oral Presentation - Observational Study - General practitioner Paramitha, Dewa Ayu Anggi; Putri, Ajeng Kartika Ayu; Ardhia, Seruni Hanna; Jutamulia, Jovita
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/v8vmp587

Abstract

Introduction & ObjectivesRanibizumab port delivery system (PDS) is a newly developed method that provides a continuous,long-term supply of ranibizumab into the vitreous, reducing the burden of monthly intravitrealinjection visits for neovascular age-related macular degeneration (nAMD) patients. This review aimsto evaluate the efficacy and safety of ranibizumab PDS in nAMD. MethodsAn extensive literature search was performed on 4 online databases: PubMed, Cochrane, ProQuest,and ScienceDirect. The inclusion criteria are human studies comparing ranibizumab port deliverysystem and intravitreal ranibizumab, English language, with full-text journal available. The mainoutcome measurements are best-corrected visual acuity (BCVA) in Early Treatment DiabeticRetinopathy Study (ETDRS) letters, central foveal thickness (CFT), and adverse events. ResultsTwo randomized controlled trials (RCTs) with a total of 638 adults were evaluated. At week 96,ranibizumab PDS reported observed mean BCVA changes from baseline (-1.0; +4.2; ETDRS letters)compared to monthly intravitreal ranibizumab (-1.1; +6.1; ETDRS letters). However, there was anincrease in mean CFT changes from baseline (+9.9; +22.3 vs ?1.3; ?35.8, ?m) and severe adverseevents frequency (22; 4 vs 4; 0) with ranibizumab PDS versus monthly intravitreal ranibizumab,respectively. ConclusionRanibizumab PDS showed comparable visual outcomes to intravitreal ranibizumab whiledemonstrating inferior anatomical outcomes and higher incidence of severe adverse effects. Despitethis, with fewer treatment visits required for up to 24 weeks, ranibizumab PDS can potentiallyreduce the treatment burden in nAMD patients with poor compliance. Further studies are needed toprovide better patient eligibility guidelines and recommendations for adverse event management ofranibizumab PDS.
Reducing Treatment Burden for Age-Related Macular Degeneration Patients: A Systematic Review of Ranibizumab Port Delivery System Paramitha, Dewa Ayu Anggi; Putri, Ajeng Kartika Ayu; Ardhia, Seruni Hanna; Jutamulia, Jovita
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/zh73sh38

Abstract

Introduction & ObjectivesRanibizumab port delivery system (PDS) is a newly developed method that provides a continuous,long-term supply of ranibizumab into the vitreous, reducing the burden of monthly intravitrealinjection visits for neovascular age-related macular degeneration (nAMD) patients. This review aimsto evaluate the efficacy and safety of ranibizumab PDS in nAMD. MethodsAn extensive literature search was performed on 4 online databases: PubMed, Cochrane, ProQuest,and ScienceDirect. The inclusion criteria are human studies comparing ranibizumab port deliverysystem and intravitreal ranibizumab, English language, with full-text journal available. The mainoutcome measurements are best-corrected visual acuity (BCVA) in Early Treatment DiabeticRetinopathy Study (ETDRS) letters, central foveal thickness (CFT), and adverse events. ResultsTwo randomized controlled trials (RCTs) with a total of 638 adults were evaluated. At week 96,ranibizumab PDS reported observed mean BCVA changes from baseline (-1.0; +4.2; ETDRS letters)compared to monthly intravitreal ranibizumab (-1.1; +6.1; ETDRS letters). However, there was anincrease in mean CFT changes from baseline (+9.9; +22.3 vs ?1.3; ?35.8, ?m) and severe adverseevents frequency (22; 4 vs 4; 0) with ranibizumab PDS versus monthly intravitreal ranibizumab,respectively. ConclusionRanibizumab PDS showed comparable visual outcomes to intravitreal ranibizumab whiledemonstrating inferior anatomical outcomes and higher incidence of severe adverse effects. Despitethis, with fewer treatment visits required for up to 24 weeks, ranibizumab PDS can potentiallyreduce the treatment burden in nAMD patients with poor compliance. Further studies are needed toprovide better patient eligibility guidelines and recommendations for adverse event management ofranibizumab PDS.
Co-Authors Anthea Casey Ardhia, Seruni Hanna Azhari, Fierda Ovita Eldinia, Lourisa Ruth Jutamulia, Jovita Putri, Ajeng Kartika Ayu